Literature DB >> 9185517

Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein.

C Gabay1, M F Smith, D Eidlen, W P Arend.   

Abstract

Interleukin 1 receptor antagonist (IL-1Ra) levels are elevated in the blood of patients with a variety of infectious, immune, or traumatic conditions. To examine whether IL1Ra is produced by liver cells with characteristics resembling an acute-phase protein, human primary hepatocytes isolated from liver biopsies and HepG2 hepatoma cells were stimulated with IL-1beta, IL-6, and TNFalpha. IL-1Ra was present in the supernatants of both cells, with production significantly enhanced by IL-1beta, and by the combination of IL-1beta and IL-6. The term IL-1Ra refers to two different proteins encoded by the same gene, but generated by alternative splicing of two different first exons. One isoform is secreted (17-kD sIL-1Ra), and the other isoform remains in the cytoplasm (18-kD icIL-1Ra). By Western blot analysis, the supernatants of human hepatoma (HepG2) cells contained only sIL-1Ra, whereas the lysates contained a novel smaller molecular mass isoform of 16 kD. RT-PCR and ribonuclease protection assay with RNA from HepG2 cells showed that only sIL-1Ra mRNA was expressed, and confirmed the inducing effect of IL-1beta and IL-6. Transfection studies were performed using constructs containing the promoters of either sIL-1Ra or icIL-1Ra coupled to the luciferase reporter gene. The sIL-1Ra promoter was active in HepG2 cells stimulated by IL-1beta and/or IL-6, whereas the icIL-1Ra promoter was inactive. Mutation of binding sites for transcription factors NF-kappaB and/or C/EBP within the proximal sIL-1Ra promoter led to significant decreases in response to IL-1beta and IL-6 in comparison to the wild-type promoter. Electromobility gel shift assays confirmed the presence of NF-kappaB and C/EBP binding sites within the sIL-1Ra promoter, and indicated a significant increase in the binding activities of nuclear proteins from HepG2 cells treated with IL-1beta and IL-6. In summary, sIL-1Ra, but not icIL-1Ra, is produced by hepatocytes, and is regulated by proinflammatory cytokines as an acute-phase protein. In addition, NF-kappaB and C/EBP family members are likely to play important roles in the full expression of IL-1Ra by hepatocytes during inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9185517      PMCID: PMC508145          DOI: 10.1172/JCI119488

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  55 in total

Review 1.  Preparation of isolated rat liver cells.

Authors:  P O Seglen
Journal:  Methods Cell Biol       Date:  1976       Impact factor: 1.441

Review 2.  Stimulation of hepatic acute phase response by cytokines and glucocorticoids.

Authors:  H Baumann; K R Prowse; S Marinković; K A Won; G P Jahreis
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

3.  Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes.

Authors:  J V Castell; M J Gómez-Lechón; M David; T Andus; T Geiger; R Trullenque; R Fabra; P C Heinrich
Journal:  FEBS Lett       Date:  1989-01-02       Impact factor: 4.124

Review 4.  The phenomenon of the acute phase response.

Authors:  I Kushner
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

5.  Hepatocyte-stimulating factor III shares structural and functional identity with leukemia-inhibitory factor.

Authors:  H Baumann; G G Wong
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

6.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

Authors:  J D Dignam; R M Lebovitz; R G Roeder
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

7.  Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B.

Authors:  L Osborn; S Kunkel; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

8.  Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis.

Authors:  A M Prieur; M T Kaufmann; C Griscelli; J M Dayer
Journal:  Lancet       Date:  1987-11-28       Impact factor: 79.321

9.  Interleukin-1 beta induces production of granulocyte colony-stimulating factor in human hepatoma cells.

Authors:  C F Lai; H Baumann
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  75 in total

1.  Protective effect of recombinant human IL-1Ra on CCl4-induced acute liver injury in mice.

Authors:  Run-Zhi Zhu; Di Xiang; Chao Xie; Jing-Jing Li; Jian-Jun Hu; Hong-Lin He; Yun-Sheng Yuan; Jin Gao; Wei Han; Yan Yu
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

2.  Anti-interleukin 1alpha autoantibodies.

Authors:  P Miossec
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

3.  Phosphoryl moieties of lipid A from Neisseria meningitidis and N. gonorrhoeae lipooligosaccharides play an important role in activation of both MyD88- and TRIF-dependent TLR4-MD-2 signaling pathways.

Authors:  Mingfeng Liu; Constance M John; Gary A Jarvis
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

Review 4.  Role of ischaemic preconditioning in liver regeneration following major liver resection and transplantation.

Authors:  D Gomez; S Homer-Vanniasinkam; A M Graham; K R Prasad
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

5.  Adipocytokines and the metabolic syndrome among older persons with and without obesity: the InCHIANTI study.

Authors:  Sari Stenholm; Annemarie Koster; Dawn E Alley; Marjolein Visser; Marcello Maggio; Tamara B Harris; Josephine M Egan; Stefania Bandinelli; Jack M Guralnik; Luigi Ferrucci
Journal:  Clin Endocrinol (Oxf)       Date:  2010-07       Impact factor: 3.478

Review 6.  Adjunct corticosteroid treatment in patients with pneumonia: A precision medicine approach.

Authors:  Srdjan Gavrilovic; Ana Andrijevic; Aida Mujakovic; Yewande Odeyemi; Belma Paralija; Ognjen Gajic
Journal:  Bosn J Basic Med Sci       Date:  2019-11-08       Impact factor: 3.363

Review 7.  Regulation of serum amyloid A protein expression during the acute-phase response.

Authors:  L E Jensen; A S Whitehead
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

8.  Polymorphisms of the IL1-receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation.

Authors:  Alexander P Reiner; Mark M Wurfel; Leslie A Lange; Christopher S Carlson; Alex S Nord; Cara L Carty; Mark J Rieder; Cindy Desmarais; Nancy S Jenny; Carlos Iribarren; Jeremy D Walston; O Dale Williams; Deborah A Nickerson; Gail P Jarvik
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-05-01       Impact factor: 8.311

9.  Large-Scale Discovery and Validation Studies Demonstrate Significant Reductions in Circulating Levels of IL8, IL-1Ra, MCP-1, and MIP-1β in Patients With Type 1 Diabetes.

Authors:  Sharad Purohit; Ashok Sharma; Diane Hopkins; Leigh Steed; Bruce Bode; Stephen W Anderson; John Chip Reed; R Dennis Steed; Tao Yang; Jin-Xiong She
Journal:  J Clin Endocrinol Metab       Date:  2015-07-09       Impact factor: 5.958

Review 10.  Why not treat human cancer with interleukin-1 blockade?

Authors:  Charles A Dinarello
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.